NuCana Future Growth
Future criteria checks 0/6
NuCana is forecast to grow earnings and revenue by 9.2% and 80.9% per annum respectively while EPS is expected to grow by 31.3% per annum.
Key information
9.2%
Earnings growth rate
31.3%
EPS growth rate
Biotechs earnings growth | 26.8% |
Revenue growth rate | 80.9% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 23 Dec 2024 |
Recent future growth updates
Recent updates
Can NuCana (NASDAQ:NCNA) Afford To Invest In Growth?
Aug 21Here's Why NuCana (NASDAQ:NCNA) Must Use Its Cash Wisely
Mar 14We're Keeping An Eye On NuCana's (NASDAQ:NCNA) Cash Burn Rate
Oct 15Here's Why We're A Bit Worried About NuCana's (NASDAQ:NCNA) Cash Burn Situation
Jul 01Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation
Mar 15Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation
Nov 30NuCana: An Intriguing 'Sum Of The Parts' Story
Sep 22NuCana GAAP EPS of -£0.07
Aug 17NuCana regains Nasdaq compliance
Jul 27NuCana: Improving Chemotherapy And A Major Patent Litigation Win Against Gilead
Jul 13Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation
May 02We Think NuCana (NASDAQ:NCNA) Can Easily Afford To Drive Business Growth
Jan 17NuCana: Preparing For A Critical 2022
Dec 08We're Interested To See How NuCana (NASDAQ:NCNA) Uses Its Cash Hoard To Grow
Sep 30NuCana: The Market Continues To Overlook Its ProTide Platform Technology
Sep 11We Think NuCana (NASDAQ:NCNA) Can Afford To Drive Business Growth
Jun 01Companies Like NuCana (NASDAQ:NCNA) Are In A Position To Invest In Growth
Feb 15How Many NuCana plc (NASDAQ:NCNA) Shares Do Institutions Own?
Dec 22NuCana (NCNA) Investor Presentation - Slideshow
Dec 02NuCana reports Q3 results
Nov 19Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2027 | 10 | -34 | N/A | N/A | 3 |
12/31/2026 | N/A | -27 | N/A | N/A | 3 |
12/31/2025 | N/A | -25 | N/A | N/A | 3 |
12/31/2024 | N/A | -23 | N/A | N/A | 3 |
9/30/2024 | N/A | -26 | -12 | -12 | N/A |
6/30/2024 | N/A | -28 | -18 | -17 | N/A |
3/31/2024 | N/A | -27 | -22 | -22 | N/A |
12/31/2023 | N/A | -28 | -27 | -26 | N/A |
9/30/2023 | N/A | -35 | -34 | -33 | N/A |
6/30/2023 | N/A | -33 | -22 | -22 | N/A |
3/31/2023 | N/A | -31 | -25 | -25 | N/A |
12/31/2022 | N/A | -32 | -24 | -23 | N/A |
9/30/2022 | N/A | -30 | -27 | -26 | N/A |
6/30/2022 | N/A | -34 | -30 | -29 | N/A |
3/31/2022 | N/A | -39 | -25 | -24 | N/A |
12/31/2021 | N/A | -41 | -25 | -24 | N/A |
9/30/2021 | N/A | -39 | -23 | -23 | N/A |
6/30/2021 | N/A | -40 | -28 | -27 | N/A |
3/31/2021 | N/A | -36 | -25 | -23 | N/A |
12/31/2020 | N/A | -31 | -23 | -22 | N/A |
9/30/2020 | N/A | -26 | -18 | -17 | N/A |
6/30/2020 | N/A | -22 | -21 | -20 | N/A |
3/31/2020 | N/A | -20 | -25 | -24 | N/A |
12/31/2019 | N/A | -21 | -25 | -24 | N/A |
9/30/2019 | N/A | -17 | -24 | -22 | N/A |
6/30/2019 | N/A | -16 | -19 | -18 | N/A |
3/31/2019 | N/A | -13 | -17 | -16 | N/A |
12/31/2018 | N/A | -14 | -14 | -12 | N/A |
9/30/2018 | N/A | -15 | -14 | -13 | N/A |
6/30/2018 | N/A | -26 | N/A | -11 | N/A |
3/31/2018 | N/A | -28 | N/A | -10 | N/A |
12/31/2017 | N/A | -23 | N/A | -9 | N/A |
9/30/2017 | N/A | -20 | N/A | -8 | N/A |
6/30/2017 | N/A | -7 | N/A | -8 | N/A |
3/31/2017 | N/A | -6 | N/A | -9 | N/A |
12/31/2016 | N/A | -6 | N/A | -9 | N/A |
12/31/2015 | N/A | -5 | N/A | -4 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NCNA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: NCNA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: NCNA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: NCNA is forecast to have no revenue next year.
High Growth Revenue: NCNA is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if NCNA's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/06 01:28 |
End of Day Share Price | 2025/01/06 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
NuCana plc is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Yigal Nochomovitz | Citigroup Inc |
Eun Kyung Yang | Jefferies LLC |
Leland Gershell | Oppenheimer & Co. Inc. |